CoChat

Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Introduction: Obesity is a global health challenge, and pharmacologic options are emerging. Once daily subcutaneous administration of 3 mg liraglutide, a glucagon like peptide-1 analogue, has been shown to induce weight loss in clinical trials, but real-world effectiveness data are scarce. Methods: It is a single-centre retrospective cohort study of patients who were prescribed liraglutide on top of lifestyle adaptations after multidisciplinary evaluation. In Belgium, liraglutide is only indicated for weight management if the BMI is >30 kg/m 2 or ≥27 kg/m 2 with comorbidities such as dysglycaemia, dyslipidaemia, hypertension, or obstructive sleep apnoea. No indication is covered by the compulsory health care insurance. Liraglutide was started at 0.6 mg/day and uptitrated weekly until 3 mg/day or the maximum tolerated dose. Treatment status and body weight were evaluated at the 4-month routine visit. Results: Between June 2016 and January 2020, liraglutide was prescribed to 115 patients (77% female), with a median age of 47 (IQR 37.7–54.0) years, a median body weight of 98.4 (IQR 90.0–112.2) kg, a BMI of 34.8 (IQR 32.2–37.4) kg/m 2, and an HbA1c level of 5.6%. Five (4%) patients did not actually initiate treatment, 9 (8%) stopped treatment, and 8 (7%) were lost to follow-up. At the 4-month visit, the median body weight had decreased significantly by 9.2% to 90.8 (IQR 82.0–103.5) kg (p < 0.001). Patients using 3.0 mg/day (n = 60) had lost 8.0 (IQR 5.8–10.4) kg. The weight loss was similar (p = 0.9622) in patients that used a lower daily dose because of intolerance: 7.4 (IQR 6.2–9.6) kg for 1.2 mg (n = 3), 7.8 (IQR 4.1–7.8) kg for 1.8 mg (n = 16), and 9.0 (IQR 4.8–10.7) kg for 2.4 mg/day (n = 14). Weight loss was minimal if liraglutide treatment was not started or stopped prematurely (median 3.0 [IQR 0.3–4.8] kg, p < 0.001, vs. on treatment). Further analysis showed an additional weight reduction of 1.8 kg in the patients that had started metformin <3 months before the start of liraglutide (p < 0.001). The main reasons for liraglutide discontinuation were gastrointestinal complaints (n = 5/9) and drug cost (n = 2/9). Conclusion: In this selected group of patients, the majority complied with liraglutide treatment over the initial 4-month period and achieved a significant weight loss, irrespective of the maximally tolerated maintenance dose. Addition of metformin induced a small but significant additional weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000520217

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Change in body weight and body mass index, 4 months after the start of liraglutide (green, n = 93) and in patients who stopped or did not start liraglutide (red, n = 10/14 patients). Eight patients were lost to follow-up and are not included in the figure.
Fig. 1 Change in body weight and body mass index, 4 months after the start of liraglutide (green, n = 93) and in patients who stopped or did not start liraglutide (red, n = 10/14 patients). Eight patients were lost to follow-up and are not included in the figure.CC-BY-NC · From the PDF
Fig. 2 Change in body weight after 4 months of treatment with liraglutide, according to the used liraglutide maintenance dose. The maximum dose reached in an individual patient was determined by side effects in the majority of patients ( n = 19), but could also be influenced by sufficient experienced weight loss ( n = 12) or injection site complaints ( n = 1).
Fig. 2 Change in body weight after 4 months of treatment with liraglutide, according to the used liraglutide maintenance dose. The maximum dose reached in an individual patient was determined by side effects in the majority of patients ( n = 19), but could also be influenced by sufficient experienced weight loss ( n = 12) or injection site complaints ( n = 1).CC-BY-NC · From the PDF
Fig. 3 Change in body weight after 4 months of treatment with liraglutide, according to intake of metformin.
Fig. 3 Change in body weight after 4 months of treatment with liraglutide, according to intake of metformin.CC-BY-NC · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 34

Metadata

Authors
Trenson, L., Trenson, S., van Nes, F., Moyson, C., Lannoo, M., Deleus, E., Meulemans, A., Matthys, C., Mertens, A., Van der Schueren, B., & Vangoitsenhoven, R.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • AZ Sint-Jan (BE)
Venue
Obesity Facts
Publisher
S. Karger AG
Published
2021-11-22
Volume
15
Issue
1
Pages
83-89
ISSN
  • 1662-4025 (ISSN-L)
  • 1662-4033
OpenAlex
W3216600551
Cited by
34
References
23
Citations by year
2026: 1 · 2025: 7 · 2024: 10 · 2023: 12 · 2022: 4
FWCI
3.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Obesity Facts (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
KU Leuven
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
liraglutide, weight loss, obesity, GLP-1 receptor agonists, dose titration, real-world effectiveness, weight management, medication adherence, drug intolerance, lifestyle modification, body mass index, Belgium, health insurance coverage, treatment discontinuation, HbA1c, dyslipidemia, hypertension, obstructive sleep apnea
MeSH terms
Liraglutide, Adult, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Weight Loss, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved. https://app.cochat.ai/papers/10.1159/000520217
The paper
Trenson, L., Trenson, S., van Nes, F., Moyson, C., Lannoo, M., Deleus, E., Meulemans, A., Matthys, C., Mertens, A., Van der Schueren, B., & Vangoitsenhoven, R. (2022). Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved. Obesity Facts. https://doi.org/10.1159/000520217

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.